Life Science Angels

Life Science Angels is elated to welcome a new portfolio company, Vivifi Medical, headed by Tushar Sharma. Learn more about how the company is developing a minimally invasive, office-based treatment for benign prostatic hyperplasia - https://lnkd.in/e2AWpz2h Vivifi's unique approach of needle-based technology is designed to reduce testosterone-rich blood flow to the prostate, addressing a potential hormonal driver of prostate growth without entering the urethra, leaving an implant, or disrupting systemic testosterone. The company's goal is to give millions of men a new option between lifelong medication and transurethral surgery: one designed to preserve urinary and sexual function while treating the underlying source of the disease.

Life Science Angels is elated to welcome a new portfolio company, StimCardio Medical, headed by Amir Soltanianzadeh. Learn more about the company and how they are developing a non-invasive, wearable neuromodulation platform for personalized therapy - https://lnkd.in/gfPckgis

Growing the strategic partners in life sciences to effectively contribute and investing in early-stage startups is one of many critical objectives of Life Science Angels. Our investors were elated to be surrounded by long-term partners and those whom we are connecting with for the first time, during the numerous meetings, panel plenary sessions, and events at the conferences by the Biotechnology Innovation Organization and Life Science Nation in San Diego this week. Interested in partnering and investing with us as an investor or strategic partner? Learn more - https://lnkd.in/g_dDtARb

The pride of our 100+ investors at Life Science Angels who are committed to and invests in life sciences exclusively for the past 20+ years, is a legacy we are proud to continue. One of the great examples of our investors in action is that of LSA’s Board Member Robert Hess, who recently represented LSA at the recent dealmaker reception hosted by Biocom in SF among VC partners, pharma ventures, and early stage startups. Interested in connecting with us to learn more about joining as our investors? Find out more - https://lnkd.in/g_dDtARb

Congratulations to our portfolio company, Noctrix Health, Inc. and the team under Shri Raghunathan on its major milestone. We are proud of yet another of Life Science Angels companies that makes a meaningful and positive impact for the patients.

Another busy and active time for our investors at Life Science Angels during the Biotechnology Innovation Organization conference week in San Diego. Among numerous events occurring, join our Priya B., who will be joining a panel hosted by Life Science Nation on the topic of "New Frontiers in Diagnostics: Investing in Technologies Enabling Earlier Disease Detection". https://lnkd.in/gVwyGdr5

At Life Science Angels, we are proud of the tradition of our 100+ stellar investors sharing their perspectives from deep expertise in life sciences. If you’re in Boston, join our Divya Yerraguntla who will be joining a panel hosted by BioTechX USA.

Beyond the formalized marquis meetings throughout the year, Life Science Angels has enjoyed the casual and social gathering of investors, founders, and partners all dedicated to life sciences, knowing and seeing that such gathering always yields building of a partnership based on trust and confidence. Working with our generous partners Ed Coady and Poonam Lata of TriNet, we’re delighted to yet again foster new and growing partnerships with experts dedicated to the life sciences industry that LSA is committed to serve.

Life Science Angels is a community of 100+ angel investors who are just passionate about life sciences. Through their investing, company-building, advising, and leadership, they bring unique expertise and perspectives to actively invest and contribute to the life sciences industry we love. We were privileged and grateful to hear from LSA investors Michael Finney, Robert Hess, and Rob Lunbeck, CFA, for generously sharing their perspectives based on their combined decades of experience in angel investing in life sciences, moderated by LSA President Peter A. Socarras, during our quarterly gathering. We thank our partners at Wilson Sonsini Goodrich & Rosati - in particular, Eric Hsu - for generously hosting us. Interested in learning more about LSA investor experience? Check us out here - https://lnkd.in/g_dDtARb

We’re proud to share a major and exciting milestone! Neurava has been awarded a $4M NIH Blueprint MedTech Optimizer award to develop a first-in-class SUDEP risk stratification and forecasting algorithm. This work brings us closer to a future where SUDEP risk is no longer uncertain, but quantifiable, actionable, and preventable. By integrating multimodal physiological data, our goal is to provide clinicians and families with objective insights to guide earlier intervention and ultimately save lives. Grateful to The National Institutes of Health Blueprint program for supporting this critical effort and to our collaborators working to advance care in epilepsy. https://lnkd.in/eMkCBBMb #Neurotech #MedTech #Epilepsy #SUDEP #DigitalHealth #NIH